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Background: Charcot-Marie-Tooth disease (CMT) is a heterogeneous disorder of the peripheral nervous system.
So far, mutations in hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional
protein), beta subunit (HADHB) gene exhibit three distinctive phenotypes: severe neonatal presentation with
cardiomyopathy, hepatic form with recurrent hypoketotic hypoglycemia, and later-onset axonal sensory neuropathy
with episodic myoglobinuria.
Methods: To identify the causative and characterize clinical features of a Korean family with motor and sensory
neuropathies, whole exome study (WES), histopathologic study of distal sural nerve, and lower limb MRIs were
performed.
Results: WES revealed that a compound heterozygous mutation in HADHB is the causative of the present patients.
The patients exhibited an early-onset axonal sensorimotor neuropathy without episodic myoglobinuria, and showed
typical clinical and electrophysiological features of CMT including predominant distal muscle weakness and atrophy.
Histopathologic findings of sural nerve were compatible with an axonal CMT neuropathy. Furthermore, they didn’t
exhibit any other symptoms of the previously reported HADHB patients.
Conclusions: These data implicate that mutation in HADHB gene can also cause early-onset axonal CMT instead of
typical manifestations in mitochondrial trifunctional protein (MTP) deficiency. Therefore, this study is the first report
of a new subtype of autosomal recessive axonal CMT by a compound heterozygous mutation in HADHB, and will
expand the clinical and genetic spectrum of HADHB.
Keywords: Charcot-Marie-Tooth disease (CMT), Whole exome sequencing (WES), HADHB, Mitochondrial trifunctional
protein (MTP)Background
Charcot-Marie-Tooth disease (CMT), also called heredi-
tary motor and sensory neuropathy, is a clinically and
genetically heterogeneous disorder of the peripheral ner-
vous system [1-3]. CMT is conventionally divided into
the demyelinating form (CMT1) and the axonal form
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reproduction in any medium, provided the orsubtypes (from CMT2A to CMT2P) according to their
distinct clinical symptoms and genetic causes [4-6].
So far, more than 60 causative genes or loci have been
reported to be associated with the CMT development
(http://www.molgen.ua.ac.be/CMTMutations/Home/
Default.cfm). However, large number of CMT patients is
waiting for uncovering their specific genetic underlying
causes. Thus efficient analysis tools such as whole exome
sequencing (WES) are required to accelerate the identifi-
cation of the underlying genetic causes. Applications of
WES to CMT have been proved as to be powerful to iden-
tify rare genetic causes from small-sized pedigrees [7-9].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tuent of inner membrane of mitochondria, exerts a sig-
nificant catalytic activity for beta-oxidation cycle, which
metabolizes long-chain fatty acyl-CoA [10]. MTP con-
sists of heterooctamer (α4β4) possessing three differ-
ent enzyme activities: long-chain enoyl-CoA hydrolase
(LCEH) and long-chain 3-hydroxy-acyl-CoA dehydro-
genase (LCHAD) activities harbored by the α-subunit
(HADHA), while β-subunit (HADHB) encode long-
chain 3-ketoacyl-CoA thiolase (LCKT) [10]. Deficiency
of MTP is an autosomal recessive disorder that exhibits
characteristic features of cardiomyopathy, hypoketotic
hypoglycemia, metabolic acidosis, sudden infant death,
metabolic encephalopathy, liver dysfunction, axonal sen-
sory neuropathy and pigmentary retinopathy [11-13].
Here, we report clinical and pathological features of an
autosomal recessive CMT family harboring a novel com-
pound heterozygous HADHB mutation, which is identi-
fied by WES.Methods
Patients
We enrolled a total of 6 members of a Korean demye-
linating CMT family (family ID: FC354) with 2 affected
individuals. The CMT phenotype of this family was
seemed to be inherited with autosomal recessive mode,
since two of three siblings were affected while both par-
ents were unaffected. No CMT patient was identified
from close relatives of the family. This study also re-
cruited 500 Korean healthy controls with no familial his-
tory of neuromuscular disorders (10-60 years old). All
samples were collected from 2011 to 2012. Informed
consent was obtained from all participants and from
parents of participants younger than 18 years of age ac-
cording to the protocol approved by the Institutional Re-
view Board for Ewha Womans University, Mokdong
Hospital (ECT 11-58-37).Clinical and electrophysiological assessments
Patients were evaluated by taking a detailed history in-
cluding motor and sensory impairments, deep tendon
reflexes, and muscle atrophy undertaken by two in-
dependent neurologists. Muscle strengths of flexor and
extensor muscles were assessed manually using the med-
ical research council (MRC) scale. In order to determine
physical disability, we used three scales, a functional dis-
ability scale (FDS) [14], and a CMT neuropathy score
(CMTNS) [15]. Sensory impairments were assessed in
terms of the level and severity of pain, temperature, vi-
bration and position. Nerve conduction studies (NCSs)
were carried out with a surface electrode in median,
ulnar, peroneal, tibial, and sural nerves as previously de-
scribed [16].MRI studies
Two patients (II-1 and -2) with HADHB mutation were
studied with MRI of the brain, hip, thigh and lower leg
using a 1.5-T system (Siemens Vision, Siemens, Germany).
Whole brains were scanned using a slice thickness of
7 mm and a 2-mm interslice gap, to produce 16 axial im-
ages. The imaging protocol consisted of T2-weighted spin
echo (TR/TE = 4,700/120 ms), T1-weighted spin echo
(TR/TE = 550/12 ms), and fluid-attenuated inversion re-
covery (FLAIR) (TR/TE = 9,000/119 ms, inversion time
2,609 ms) images. Lower leg imaging was carried out in
axial [field of view (FOV) 24-32 cm, slice thickness 10 mm,
and slice gap 0.5-1.0 mm] and coronal planes (FOV
38-40 cm, slice thickness 4-5 mm, slice gap 0.5-1.0 mm).
Histopathological studies
Histopathological analysis of the distal sural nerve was
performed in a patient (II-2). The density of myelinated
fibers (MFs), axonal diameter, and myelin thickness were
determined directly from the semi-thin transverse sections
using a computer-assisted image analyzer (AnalySIS, Soft
Imaging System, Germany). Ultrathin cut samples (60 ~
65 nm) are contrasted with uranyl acetate and lead cit-
rate for ultrastructural study (H-7650, Hitachi, Japan).
DNA preparation and whole exome sequencing
Total DNA was purified from peripheral blood using
QIAamp blood DNA purification kit (QIAGEN, Hilden,
Germany). DNAs were prescreened for duplication of
17p12 (PMP22) and mutations in the coding exons of
GJB1, MPZ, NEFL and MFN2 as previously described
[9]. Exome sequencing and subsequent filtering was per-
formed as previously described [9].
Determination of exon5 splicing and DNA cloning
Total mRNA was purified from proband’s fibroblast using
RNeasy minikit (QIAGEN). Then cDNA was synthe-
sized using Superscript reverse transcriptase (Invitrogen,
Carlsbad, CA). For amplification of wildtype and mutant
HADHB, following primers are used: HADHB forward,
5′-ACG TCA GCC AAG ATT CCA GA-3′, and HADHB
reverse, 5′-GCA CAG AAA CTT CAG GTC ACT TC-3′.
Sequencing was performed to determine cDNA sequence
of each amplified mutant allele. Amplified cDNAs were
cloned into pCR2.1-TOPO vector (Invitrogen) and sub-
sequently moved into expression vector, pCMV-myc
(Clontech, Mountain View, CA).
DNA transfection and determination of protein half-life
HEK293 cells (2 × 105) were transfected with control
vector, pCMV-myc, and cloned HADHB cDNAs using
FuGene transfection reagent (Promega, Madison, WI).
For determination of half-life of HADHB, cyclohexamide
(100 μM) was treated after 20 hr of transfection.
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Protein expression in fibroblast and HEK293 cells were de-
termined by standard Western blotting. Anti-HADHB Ab
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-myc Ab
(Abcam, Cambridge, UK), anti-actin Ab, anti-mouse sec-
ondary Ab, anti-rabbit secondary Ab (Sigma, St. Louis,
MO), and ECL plus Western blotting substrate (Thermo
Scientific, Rockford, IL) were used for detection of protein.
Results
Identification of a compound heterozygous mutation in
HADHB
To identify the underlying genetic cause of this family,
WES was performed for five members (I-1, I-2, II-1, II-2,Figure 1 Pedigree and HADHB mutations in FC354. (A) Alleles of two H
symbols, affected; arrow, proband; asterisks, individuals underwent WES. (B
Vertical arrows indicate the mutation site. (C) Conservation analysis of amin
red; partial conserved amino acids, blue. (D) Deletion of exon5 in c.210-1G
HADHB in the proband’s fibroblast. Ctr1, normal control fibroblast; and Ctr2
HADHB gene.and II-4). Total sequencing yields was 10.11Gbp/sample,
and mappable reads were 93.1%. Total number of variants
(SNPs and indels) was 80,301 single nucleotide variants
(SNVs)/sample, of which 20,430 SNVs were coding
variants (Additional file 1: Table S1). Several functionally
significant variants were identified in the CMT-relevant
genes; however, no variant was fitted for autosomal reces-
sive inheritance of the family (Additional file 1: Table S2).
Moreover, most of them were also observed in controls.
From the unreported or rare functionally significant
SNVs reported in dbSNP135 and 1000 Genome project
database, we could identify two pairs of compound hetero-
zygous mutations transmitted from each of the parents:
[c.210-1G > C] + [c.686G > T] in HADHB (NM_000183)ADHB mutations were indicated. Open symbols, unaffected; filled
) Sequencing chromatograms of c.686G > T and c.210-1G > C mutation.
o acid sequences among species. Complete conserved amino acids,
> C allele was confirmed by cDNA sequencing. (E) Expression level of
-7, fibroblast from CMT patients with mutation in other than
Table 1 Electrophysiological features of patients with
mutations in HADHB gene
Patients II-1 II-2 Normal value
Age at exam (years) 37 32 34
Median nerve
TL (ms) 4.2 4.1 4.1 < 3.9
CMAP (mV) 7.2 2.2 3.6 > 6.0
MNCV (m/s) 44.9 40.6 41.9 > 50.5
F-wave (ms) 36.8 55.0 38.8 < 28.0
Ulnar nerve
TL (ms) 3.5 4.0 4.0 < 3.0
CMAP (mV) 5.7 5.2 5.8 > 8.0
MNCV (m/s) 40.4 43.1 43.9 > 51.1
F-wave (ms) 33.2 36.8 34.4 < 29.0
Peroneal nerve
TL (ms) A A A < 5.3
CMAP (mV) A A A > 1.6
MNCV (m/s) A A A > 41.2
F-wave (ms) A A A < 49.0
Tibial nerve
TL (ms) 3.9 A A < 5.4
CMAP (mV) 0.2 A A > 6.0
MNCV (m/s) 34.0 A A > 41.1
F-wave (ms) 63.0 A A < 52.1
Median sensory nerve
SNAP (μV) A A A > 8.8
SNCV (m/s) A A A > 39.3
Ulnar sensory nerve
SNAP (μV) A A A > 7.9
SNCV (m/s) A A A > 37.5
Sural nerve
SNAP (μV) A A A > 6.0
SNCV (m/s) A A A > 32.1
Bold character indicates abnormal values. A, absent potentials; TL, terminal
latency; CMAP, compound muscle action potential; MNCV, motor nerve
conduction velocity; SNAP, sensory nerve action potential; SNCV, sensory
nerve conduction velocity; NP, no potential.
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kinase-like 4 (CDKL4, NM_001009565). Since the CDKL4
compound mutations were found in Korean healthy con-
trols, the HADHB compound heterozygous mutation was
finally considered as the underlying cause of the axonal
CMT (Figures 1A and B). The p.Arg229Leu mutation site
locating in the thiolase N domain is highly conserved be-
tween different species (Figure 1C) and is predicted to
affect the functional integrity by in silico analysis (SIFT
and PolyPhen2). The other mutation, c.210-1G > C, is pre-
dicted and experimentally proved to result in the loss of
exon 5 by improper splicing (Figure 1D).
Western blotting revealed that expression level of
HADHB from the proband’s fibroblast is quite lower than
those from controls (Figure 1E). Additionally, Western
blotting revealed that the mutant proteins expressed
in HEK293 cells are more unstable than wild-type
(Additional file 2: Figure S1). Cyclohexamide treat-
ment demonstrated that the half-life of wild-type
HADHB is quite short (less than 2 hr). Thus these
results are consistent with the lowered level of HADHB
in patients.
Clinical manifestations
The proband (Figure 1A, II-2) was born from non-
consanguineous Korean parents. He noticed lower leg
weakness, which resulted in bilateral foot drop and gait
disturbance at 5 years. At 12 years old, he used a walker
due to progressively impaired gait. Neurologic examin-
ation at 34 years of age revealed that muscle weakness
and atrophy began and the distal part of the lower limbs
was prominently involved. Toe and heel gait defects
were found. Vibration and position senses were more se-
verely disturbed than pain and temperature senses. Deep
tendon reflexes were absent in all extremities, but pa-
thologic reflexes were not found. An echocardiogram
showed normal and there was no evidence of intermittent
rhabdomyolysis or retinal dysfunction. Ophthalmological
examination including dilated fundus examination was
done in both patients, but pigmentary retinopathy was not
observed. Laboratory findings showed a total carnitine
level of 33.4 μmol/L (reference interval: 45-91 μmol/L),
a free carnitine level of 24.5 μmol/L (reference interval:
36-74 μmol/L), and acylcarnitine level of 10.9 μmol/L
(reference interval: 36-74 μmol/L).
His 37-year-old elder sister (II-1) began with distal
limb weakness and gait disability from 6 years old and
became to use a walker from 15 years old. At 23 years,
she underwent an operation of bilateral feet due to walk-
ing difficulties. When we examined her at 37 years,
she also revealed muscle weakness and atrophies of
bilateral distal muscles of the upper and lower limbs.
Loss of sensory and tendon reflexes were similar to
the proband. The other family members were provennormal by careful clinical and electrophysiological
examination.
The nerve conduction studies (NCSs) revealed that
motor nerve conduction velocities (MNCVs) of median,
ulnar, peroneal and tibial nerves in both patients were
abnormal (Table 1). Except median nerve of II-1, all
compound muscle action potentials (CMAPs) were
below the normal range. Sensory nerve action potentials
(SNAPs) of all tested nerves were lost. Needle electro-
myography (EMG) was compatible with neuropathy with
fibrillation potentials and neurogenic motor unit action
potentials (MUAPs).
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Histopathological analysis of the distal sural nerve was
performed in the proband at 34 years of age. Semi-thin
transverse sections with toluidine blue stain showed ab-
sence of large myelinated fibers (MFs) with remaining
medium and small-sized MFs, and occasionally noted re-
generating axonal clusters (Figure 2A). Thin MFs were
frequently noted and remaining MFs (4,366/mm2) were
less than control (45-year-old male: 7,300/mm2). The
average of diameter of MFs and MF% area were also
quite lower than control (Figure 2B). Electron micro-
scopic examination revealed MFs with pseudo-onion
bulb formation, occasionally noted regenerating clusters,
and rarely noted demyelinated axon and thin MFs
(Figures 2C and D). Several myelinated and unmyelin-
ated axons showed swelling or vacuolization of axoplasm,
swollen or abnormal mitochondria, and abnormal mem-
branous structures.Figure 2 Histopathological findings of distal sural nerve biopsy in
revealed absence of large MFs and remaining medium and small-sized
noted axonal clusters (curved arrow). (B) Histogram showed unimodal
micrographs revealed MFs with pseudo-onion bulb formation and a th
A, x400; C, x3000; and D, x10000.Lower limb MRI findings
Brain and pelvic MRIs showed normal findings (data not
shown), but lower limb MRIs of both patients revealed
hyperintense signal abnormalities (Figure 3). T1-weighted
images demonstrated selective muscle atrophies with sig-
nal changes, which were more prominent in lower leg
muscles than thigh or pelvic muscles, thereby being con-
sistent with the hypothesis of length-dependent axonal
neuropathy. At the thigh level, there were severe involve-
ments of the semitendinosus, sartorius and gracilis mus-
cles, but a sparing of vastus group and adductor muscles.
The lower leg MRI revealed marked involvement of tibi-
alis anterior, peronei, extensor digitorum and halluces
longus muscles; however, soleus muscles were sparing.
Discussion
Mitochondrial trifunctional protein (MTP) exerts a sig-
nificant catalytic activity for last three steps of long chainII-2. (A) Toluidine blue-stained semi-thin transverse section
MFs with frequently noted thin MFs (arrows) and occasionally
distribution pattern of MF diameter. (C and D) Electron
in MF compatible with remyelination. Original magnifications:
Figure 3 Thigh and lower leg MRIs in II-1 (A and C) and II-2 (B and D). (A and B) At the thigh level, MRIs demonstrated severe muscle
atrophied with signal changes of semitendinous muscles of posterior compartment, gracilis muscle of medial compartment, and sartorius muscle
of anterior compartment. (C and D) The lower leg MRIs revealed selective severe muscle atrophy with signal change of anterior (arrow; tibialis
anterior, extensor digitorum and halluces longus muscles) and lateral (arrowhead; peronei muscles) compartments. However, posterior
compartment muscles (soleus and tibialis posterior muscles) were sparing in the later stages.
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α-subunit (HADHA) and β-subunit (HADHB) [10]. To
date, 33 mutation sites in HADHB gene have been re-
ported [17] and these mutation-associated phenotypes
exhibit clinical heterogeneity, which can be mainly sub-
divided into three distinctive groups: severe neonatal
presentation with cardiomyopathy, hepatic form with re-
current hypoketotic hypoglycemia, and later-onset axonal
sensory neuropathy with episodic myoglobinuria [11].
Several research groups have attempted to elucidate
the underlying genotype-phenotype correlation of the
HADHB gene. Spiekerkoetter et al. analyzed mutations
from 15 patients and linked clinical phenotype with the
location of the mutation [18]. They postulated that mu-
tations in the outer loop were present only in milder
forms. In addition, they suggested that the degree of re-
duction of cross-reactive immunological material (CRIM)
is also correlated with the severity of clinical presentation.
Purevsuren et al. also demonstrated the positive correla-
tions between residual enzymatic activity and phenotypic
severity using in vitro functional study [19]. Collectively,
although MTP deficiency is recessive and highly heteroge-
neous, there are strong correlations between phenotypic
severity and residual enzymatic activity or CRIM amounts
of mutant proteins.
According to the crystal structure of HADHB, present
mutation, Arg229Leu, locates in the outer loop [20]. This
implicates that Arg229Leu mutation might mildly affect
LCKT activity, while splicing variant of C.210-1G > C,
which results in deletion of 15 amino acids, was predicted
to have severely affected LCKT activity. In contrast tothese predictions, however, overexpression of these mu-
tants revealed that mutant proteins primarily possess lo-
wer stability than wild type. These results might come
from the conformation changes of their structures, there-
by translated misfolded proteins are subsequently degra-
ded by proteases. Therefore, the loss of the enzymatic
activity by the mutations might be greater than predicted.
To unveil the effect of HADHB deficiency on periph-
eral nerve, we first analyzed the expression of HADHB
in distal sural nerve. Transcriptome analysis from 14
control samples confirmed the expression of HADHB in
the distal sural nerve (data not shown). In addition, we
tried to demonstrate the effect of HADHB deficiency on
peripheral nerve; however, the effects of HADHB knock-
down on the responses to oxidative stress and cell
proliferation of mouse motor neuron were not within
statistically significant ranges (data not shown). Therefore,
further analyses are needed to elucidate the pathophysio-
logical mechanism of HADHB mutation-mediated peri-
pheral neuropathy.
Clinical and histopathological features of the present
patients were consistent with an early-onset axonal sen-
sorimotor CMT neuropathy. Both patients revealed the
age at onset below 10 years old, and showed typical clin-
ical phenotypes of CMT including predominant distal
muscle weakness and atrophy, pes cavus, and steppage
gait (Additional file 3: Figure S2). Nerve conduction
studies in both of them were compatible with motor and
sensory neuropathies. However, they did not have any
other previously reported symptoms of HADHB patients,
such as a rhabdomyolysis, cardiomyopathy, hypoketotic
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tion, nor pigmentary retinopathy [11]. Moreover, distal
sural nerve biopsy in II-2 patient revealed typical axonal
neuropathy. It is noteworthy that swollen or abnormal
mitochondria were noted in several MFs and unmyeli-
nated axons, of which significance was uncertain. Previ-
ously loss of MFs with features of Wallerian degeneration
[21] and axonal and myelin degeneration [18] were re-
ported in HADHB patients. MRI analysis indicated a mus-
cular involvement in the present patients with HADHB
mutation. In addition, lower limb MRI findings revealed
severe muscle atrophy with hyperintense signal changes in
the lower leg muscles than those in the thigh or hip mus-
cles, which was compatible with the typical features of the
length-dependent axonal degeneration.
Conclusion
In conclusion, we first report that a heterozygous muta-
tion in HADHB causes early-onset axonal CMT without
any typical clinical symptom of MTP based on the data
from WES, MRI, and histopathological and electrophysio-
logical analysis. Thus our findings suggest that HADHB
gene can be also filed as a causative of CMT, which ex-
pands the clinical spectrum of both HADHB related di-
sease and hereditary motor and sensory neuropathy.
Additional files
Additional file 1: Table S1. Summary of exome sequencing data for
5 samples. Table S2. Polymorphic functionally significant variants in
CMT-relevant genes.
Additional file 2: Figure S1. (A) Western blotting of wild-type (WT),
c.686G > T and c.210-1G > C mutants expressed in HEK293 cells.
Cyclohexamide (CHX) was treated for indicated time. First lane, cells
transfected with pCMV-myc control vector. (B) Western blotting of
proband’s fibroblast after treatment of CHX. Ctr5-7, fibroblast from CMT
patients with mutation in other than HADHB gene.
Additional file 3: Figure S2. Leg pictures of the patient (II-2). The
patient showed prominent distal muscle atrophies of both lower
extremities and revealed typical CMT phenotypes of pes cavus, and
steppage gait.
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